Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (1159)	6/1/2000 10:49:00 PM
From: nohalo	Read Replies (1) \| Respond to of 52153

JM: You have a point here, and there may be some potential for insider trading. However, most trials are now multicentred, and vast amounts of data has to be analyzed to achieve a statistical significance, the holy grail of trials. I do not believe that any one field investigator would have access to that amount of data, which includes target outcomes, side-effects, end-points, toxic effects, relationship to placebos etc. In my opinion, an investigator would generally be taking a big risk if he were to trade on the basis of his own personal observation, without access to all the data, and the statistical analysis. Having said this, I know many MDs who follow the biotechs assiduously, and do careful and reasoned DD, before they invest. A significant number post on SI. I also know many other professionals, like lawyers and accountants and others who do the same, and who also enable us to learn more, and invest with more confidence. All of them have my respect.